JACC scientific statement on HFpEF
The Journal of the American College of Cardiology (JACC) published a scientific statement on HFpEF . This statement reviews the epidemiology, pathophysiology, diagnosis, and treatment of HFpEF.
The incidence of HFpEF is rising. Although progress has been made in understanding the pathophysiology and the development of tools for diagnosis of HFpEF, HFpEF remains underdiagnosed. Patients with HFpEF have a poor prognosis, but recent trials have shown beneficial effects of SGLT2 inhibitors in this patient population. Another important topic in this field is pathophysiological-based phenotyping of HFpEF as HFpEF is a heterogenous disease. Phenotyping of HFpEF is needed to better characterize and treat individual patients. These aspects are in-depth discussed in the JACC scientific statement.